Ann Lab Med.  2018 Mar;38(2):172-175. 10.3343/alm.2018.38.2.172.

Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma

• Lee T
• Park BG
• You E
• Cho YU
• Jang S
• Lee SM
• Suh C
• Park CJ

• KMID: 2403365
• DOI: http://doi.org/10.3343/alm.2018.38.2.172

Abstract

No abstract available.

MeSH Terms

B-Lymphocytes*
Bone Marrow*
Humans
Lymphoma, B-Cell*
Lymphoma, T-Cell*
T-Lymphocytes*

Figure

• 

  Fig. 1 Pathological findings of cervical lymph node biopsy. (A) Polymorphic infiltrate of small- to medium-sized lymphocytes with clear cytoplasm, distinct cell membrane, and mild cytological atypia, and increased high endothelial venules (H&E stain, ×400). (B) Positivity for CD4 in small- to medium-sized lymphocytes and (C) for CD21 in irregularly expanded meshwork of follicular dendritic cells (IHC stain, ×400). (D) Strong positivity of Epstein-Barr Virus (EBV) in the nuclei of immunoblasts (EBV in situ hybridization, ×400).

• 

  Fig. 2 Peripheral blood and bone marrow findings. (A) Leukoerythroblastic reaction (Wright stain, ×1,000). (B) Interstitial infiltration of large lymphoid cells with background fibrosis (H&E stain, ×400). (C) Large neoplastic lymphoid cells with CD20 positivity and (D) CD3 negativity (IHC stain, ×400).

Reference

1. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer;2008. p. 309–311.

2. Hawley RC, Cankovic M, Zarbo RJ. Angioimmunoblastic T-cell lymphoma with supervening Epstein-barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med. 2006; 130:1707–1711. PMID: 17076535.

3. Xu J, Tang Y, Zhao S, Zhang W, Xiu Y, Liu T, et al. Angioimmunoblastic T-cell lymphoma with coexisting plasma cell myeloma: a case report and review of the literature. Tohoku J Exp Med. 2015; 235:283–288. PMID: 25816919.

4. Foucar K, Reichard K, Czuchlewski D, editors. Bone marrow pathology. 3rd ed. Chicago: American Society for Clinical Pathology;2010. p. 557–577.

5. Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol. 2007; 137:416–422. PMID: 17488486.

6. Zettl A, Lee SS, Rudiger T, Starostik P, Marino M, Kirchner T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002; 117:368–379. PMID: 11888076.

7. Choi YH, Kim HS, Nam SB, Kang HJ, Na II, Yang SH, et al. A case of Epstein-Barr virus-positive diffuse, large B-cell lymphoma after angioimmunoblastic T-cell lymphoma. Korean J Hematol. 2008; 43:174–178.

8. Zhou Y, Rosenblum MK, Dogan A, Jungbluth AA, Chiu A. Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma. J Hematop. 2015; 8:235–241. PMID: 27559423.

9. Kasahara H, Kakimoto T, Saito H, Akuta K, Yamamoto K, Ujiie H, et al. Successful treatment with rituximab for angioimmunoblastic T-cell lymphoma. Leuk Res Rep. 2013; 2:36–38. PMID: 24371775.

10. Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012; 97:1594–1602. PMID: 22371178.